Submitted by Anonymous (not verified) on 9 October 2023 - 14:50
Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Anemia;Myelodysplastic Syndromes;beta-Thalassemia, Date of authorisation: 25/06/2020, Revision: 5, Status: Authorised
Source: